This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. treatment with IVIg, corticosteroids or plasma-exchange in the 6 weeks before treatment; multifocal motor neuropathy; and failure to respond to IVIg or corticosteroids.
Health technology
Two 6-week treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) were examined. The treatments were prednisolone (PRE) and intravenous immunoglobulin (IVIg). The regimen for PRE was 60 mg/day during the first 2 weeks, 40 mg/day in week 3, 30 mg/day in week 4, 20 mg/day in week 5, and 10 mg/day in week 6. IVIg consisted of 2 g Sandoglobulin (Novartis) per kg of body weight (a standard weight of 75 kg was used for the analysis).
Type of intervention
Treatment.
Economic study type
Cost-utility analysis.
Study population
The study population comprised adult patients fulfilling the following inclusion criteria: a clinical diagnosis of CIDP; progressive or relapsing motor and sensory dysfunction of more than one limb over more than 2 months caused by neuropathy; reduced or absent tendon reflexes; less than 10 white cells/microL in the cerebrospinal fluid; fulfilment of neurophysiological criteria for CIDP; significant physical disability in upper or lower limb function; and a stable or worsening clinical condition.
The exclusion criteria were: associated systematic diseases that could be associated with neuropathy; actual or planned pregnancy; concurrent medical conditions that could affect treatment; significant respiratory impairment;
Study design
This was a prospective, double-blind, crossover, randomised clinical trial that was carried out in nine European centres (the UK, Belgium, Italy, Spain, the Netherlands, Greece and the Czech Republic). The method of randomisation was not described. The first treatment period lasted 6 weeks, followed by a 4-week washout period, after which the second 6-week treatment period with the other intervention began. However, only data from the baseline and first treatment periods were used. No patient was lost to the follow-up assessment.
Analysis of effectiveness
The analysis of the clinical study appears to have been restricted to treatment completers only. The primary outcome measures used were improvements in disability scores and quality of life. Disability scores were assessed using an 11-point scale. Quality of life was examined using the EuroQol EQ-5D instrument, which contains five domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The study groups were comparable at baseline.
Effectiveness results
There were no statistically significant differences in the disability score between the two groups, although the greatest improvement was observed in the PRE group.
Quality of life was relatively unchanged (0.64 to 0.63) for the PRE group, (p=0.956), whilst there was a relatively large improvement in the utility score (from 0.57 to 0.69) in the IVIg group, (p=0.072).
